Mirvetuximab Soravtansine and Olaparib for Ovarian, Peritoneal, and Fallopian Tube Cancer
This study is looking at a combination of two drugs, Mirvetuximab Soravtansine and Olaparib, as a maintenance treatment for women with recurrent ovarian, peritoneal, or fallopian tube cancer that has responded to platinum-based chemotherapy. Researchers want to see if this combination can help prevent the cancer from growing or coming back for a longer time. Mirvetuximab Soravtansine targets a specific protein on cancer cells, and Olaparib works by interfering with how cancer cells repair their DNA. You may be able to join if you are a woman aged 18 to 100 with a specific type of ovarian, peritoneal, or fallopian tube cancer, and you are able to sign the consent form. The study aims to enroll 53 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. The study plans to enroll 53 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Progression-free survival will be measured through study completion, with an average of 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of Colorado, DenverInvestigator-initiated
~53 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Mirvetuximab Soravtansine-gynxOlaparib
At a glance
Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To measure progression free survival (PFS) with the use of MIRV combined with Olaparib in women with recurrent platinum sensitive ovarian, peritoneal, and fallopian tube cancer.
Measured over Through study completion, average of 12 months
Conditions
Where it's being run
6 sites across 5 statesPennsylvania2
California1
Colorado1
Illinois1
Wisconsin1
Study leadership
- Bradley Corr, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provision to sign and date the consent form
Stated willingness to comply with all study procedures and be available for the duration of the study
Be a woman aged ≥18 years of age
Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer
Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of prior platinum therapy (not inclusive of current/most recent platinum therapy)
Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy
Patients must have available archival tissue block or slides to confirm FRalpha positivity
Patients' tumor must have FRalpha high or medium expression
Prior anticancer therapy:
Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease.
Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles
Most recent prior chemotherapy regimen must have been platinum based
Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy
Neoadjuvant +/- adjuvant therapies are considered 1 line of therapy
Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently)
Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
Prior Bevacizumab use is allowed, but concurrent use with study combination is prohibited.
Cycle 1 Day 1 of trial therapy must be within 8 weeks of last dose of previous chemotherapy.
Patients must have adequate hematologic, liver, and kidney function as defined as:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/µL)
Platelet count ≥ 100 x 109/L (100,000 µL)
Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days
Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test
Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN
Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN)
Serum albumin ≥ 2 g/dL
Exclusion
Patients with clear cell, mucinous, sarcomatous, low grade/borderline, germ cell, or sex-cord stromal type ovarian tumor
Patients who have progressed through most recent chemotherapy regimen. Stable disease (SD) is permissible.
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions require ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:
Uncontrolled major seizure disorder
Unstable spinal cord compression
Any psychiatric disorder that prohibits obtaining informed consent.
Active hepatitis B or C infection (whether or not on active antiviral therapy)
Immunocompromised patients, e.g., patient who are known to be serologically positive for human immunodeficient virus(HIV)
Active cytomegalovirus infection
Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV
Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
Patients with clinically significant cardiac disease including, but not limited to, any of the following
Myocardial infarction ≤ 6 months prior to first dose
Uncontrolled ventricular arrhythmia, recent (within 3 months)
Superior vena cava syndrome
Unstable angina pectoris
Uncontrolled congestive heart failure (New York Heart Association \> class II)
Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
Uncontrolled cardiac arrhythmias
Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment
Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD) or Extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan , including noninfectious pneumonitis
Persistent toxicities (\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia
Patients requiring use of folate-containing supplements (eg, folate deficiency)
Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.
Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
Patients with prior hypersensitivity to monoclonal antibodies (mAb)
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
Women who are pregnant or breastfeeding, and who do not agree to use a highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV and at least 6 months after the last dose of Olaparib. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of study entry.
Patients who received prior treatment with MIRV or other FRα- targeting agents
Patients with duodenal stent or other GI disorder/defect that would interfere with absorption of oral medication
Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
Patients with known untreated or symptomatic central nervous system (CNS) metastases
Patients with a history of other malignancy within 3 years prior to enrollment
Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible
Prior known hypersensitivity reaction to study drugs and/or any of their excipients
Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Inability to comply with study and follow-up procedures
Patients deemed otherwise clinically unfit for clinical trial per investigators discretion
What this trial measures
- To measure progression free survival (PFS) with the use of MIRV combined with Olaparib in women with recurrent platinum sensitive ovarian, peritoneal, and fallopian tube cancer.Through study completion, average of 12 months
PFS will be defined as the time from first dose of MIRV and Olaparib until investigator-assessed radiologic PD or death, whichever occurs first